SCHEMBL3528703

SCHEMBL3528703

Cc1nc(C2CCN(C(=O)OC(C)(C)C)CC2)sc1CCl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
THRB P10828 1/20 0.46
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
ALDH1A1 P00352 2/20 0.43
GAA P10253 2/20 0.43
LMNA P02545 1/20 0.43
GLS O94925 2/20 0.42
GPR119 Q8TDV5 6/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.41
HTT P42858 2/20 0.40
HPGD P15428 2/20 0.40
HSD17B10 Q99714 2/20 0.39
USP2 O75604 1/20 0.39
TSHR P16473 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1118433 0.89 KDM4E (0.46) KDM4EMAPTTHRBALDH1A1GAA
SCHEMBL28772121 0.83 L3MBTL1 (0.38) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL3327723 0.81 L3MBTL1 (0.48) KDM4EMAPTTHRBMEN1KMT2A
SCHEMBL2808723 0.80 KDM4E (0.46) KDM4EMAPTTHRBGLSGPR119
SCHEMBL1118314 0.78 KDM4E (0.44) KDM4EMAPTTHRBSMN1; SMN2ALDH1A1
SCHEMBL28431381 0.77 MEN1 (0.49) KDM4EMAPTTHRBMEN1KMT2A
SCHEMBL907209 0.77 GPR119 (0.58) KDM4EMAPTTHRBMEN1KMT2A
SCHEMBL1422597 0.76 GPR119 (0.42) KDM4EMAPTTHRBMEN1KMT2A
SCHEMBL3840153 0.76 KDM4E (0.42) KDM4EMAPTTHRBKMT2ASMN1; SMN2
SCHEMBL28424325 0.76 HTT (0.46) KDM4EMAPTTHRBLMNAGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1931337-B1 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2013-10-23 EP disclosed
EP-1931337-B1 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2013-10-23 EP disclosed
US-7709481-B2 Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals SANOFI-AVENTIS (FR) 2010-05-04 US disclosed
US-7709481-B2 Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals SANOFI-AVENTIS (FR) 2010-05-04 US disclosed
US-7709481-B2 Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals SANOFI-AVENTIS (FR) 2010-05-04 US disclosed
US-20080261979-A1 Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals SANOFI-AVENTIS (FR) 2008-10-23 US disclosed
US-20080261979-A1 Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals SANOFI-AVENTIS (FR) 2008-10-23 US disclosed
US-20080261979-A1 Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals SANOFI-AVENTIS (FR) 2008-10-23 US disclosed
EP-1931337-A2 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2008-06-18 EP disclosed
WO-2007039177-A2 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 WO disclosed
WO-2007039177-A2 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261979-A1 Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals PPARD, PPARA, PPARG KDM4E 2087/4885MAPT 4444/4885THRB 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.